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ABSTRACT

An abstract of the thesis of Ksenia Andrukhiv Everton for the Master of
Science in Biology presented on May 13, 2008.

Title: The role of mitochondrial ATP-sensitive potassium channel in
cardioprotection.

Mitochondrial ATP-sensitive potassium channel (mitoKArP) has been
suggested to be the mediator of cardiac preconditioning. All of the diverse
pharmacological and physiological agents that open mitoKArP provide
protection against ischemia-reperfusion injury. Some investigators have
pointed out that some of these mitoKArP channel openers also inhibit succinate
dehydrogenase (SDH), complex II of the electron transport chain. Based on
this observation they suggest that it is the inhibition of SDH, and not the
opening of mitoKArP channel, that mediates the observed cardioprotection. In
this study, I examined four chemically distinct and unrelated pharmacological
agents, diazoxide, 3-Nitropropionic Acid (3-NPA), Protein Kinase G (PKG),
and 4'ERACK, all of which have been shown to open mitoKArP, to demonstrate
that the said cardioprotective effect mediated by mitoKArP is entirely
independent of SDH. Light scattering technique was utilized to measure the

state of mitoKATP (open/closed) by measuring mitochondrial volume. An
electrode that measures oxygen concentration was utilized to measure
mitochondrial respiration. The results of this study confirm that two of the
drugs, diazoxide and 3-NPA, inhibit succinate-supported respiration in high
doses (IC50 = 140µM and IC50 = 1.05mM, respectively). Both of these drugs,
however, do not inhibit succinate-supported respiration at the concentration
necessary to open mitoKATP (30µM and 10nM, respectively). PKG and
4Je:RACK, the other two mitoKATP openers tested in this study, do not inhibit
succinate-supported respiration at any concentration tested. These results
support the hypothesis that potassium channel openers mediate
cardioprotection through the opening of mitoKATP and not through the inhibition
of SDH.
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1. Introduction and Literature Review
1.1 Heart Attacks and Infarct
Heart attacks and their associated complications are the number one
cause of death in the United States and worldwide. According to the
American Heart Association there are over a million new and recurrent
coronary attacks per year, and of these about 38 percent will result in death
[1 ]. In addition, World Health Organization reported that acute myocardial
infarction is the leading cause of death throughout the world in both men and
women. During coronary thrombosis, commonly associated with
atherosclerotic plaque in blood vessels, blood flow through the circulatory
system is obstructed resulting in lack of nutrients and oxygen to the heart.
Prolonged lack of nutrition may lead to tissue death, also known as infarction.
Infarction and other known damage-causing aspects of a heart attack are
induced by apoptotic and necrotic cell death mechanisms. This tissue
damage is irreversible and begins within approximately 20 minutes of
occlusion. Because infarcted tissue cannot regenerate and thus permanently
decreases the size of functional cardiac tissue, return of blood flow should be
accomplished as soon as possible [2].
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1.2 Normoxic Mitochondria
Mitochondria are highly abundant eukaryotic organelles that have been
essential to the evolution of complex organisms and are the site of aerobic
respiration. They are bound by two specialized membranes (Figure 1) that
together create two mitochondrial compartments: intermembrane space
(between the two membranes) and the internal matrix (within the inner
membrane). The matrix is the site of the citric-acid cycle and the highly
convoluted inner membrane is the site of oxidative phosphorylation and the
locus of mitochondrial ATP-sensitive potassium channel (mitoKATP). The
outer membrane contains large numbers of integral proteins called porins,
which form large aqueous channels through the lipid bilayer making it highly
permeable to molecules of 5000 daltons or less. The inner membrane, on
the other hand, is highly selective and largely impermeable to ions.
Permeability to ADP, ATP, substrate anions and to Na+, K+ and Ca 2+ is
mediated largely by specific channels and carriers. A tight protonelectrochemical gradient is maintained across this membrane in order to
support the mechanism of ATP synthesis. The electron transport chain and
ATP synthase are located within the inner membrane, which has a large
surface area due to its cristae (or folds) in order to support these
mechanisms.
Proper function of the heart requires a large amount of cellular energy
and over 90% of cardiac metabolism is aerobic [3]. In order to maintain this
2

metabolism, heart cells have a high oxidative capacity. It has been estimated
that 25-35% of total cardiomyocyte volume is occupied by mitochondria [4].
About two-thirds of the ATP hydrolyzed by these mitochondria is utilized in
the contractile apparatus of the heart, while the remaining is used in active
transport in order to maintain ion balance, especially by sarcoplasmic
reticulum Ca 2+ -ATPase and the sarcolemmal Na+/K+ -ATPase [3]. In addition
to being the site of the electron transport chain and the citric acid cycle, the
mitochondria are responsible for mediating necrosis and apoptosis.
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Figure 1. Internal structures of mitochondria (modified from
http://www.cartage.org).
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1.3 lschemia-Reperfusion Injury
During cardiac ischemia, blood flow to the heart decreases or stops
completely, thus oxygen delivery to the mitochondria by and large ceases.
The citric acid cycle is arrested and therefore no energy is available from
oxidative phosphorylation. Non-esterified fatty acid levels rise leading to an
accumulation of cytoplasmic NADH resulting in a severalfold rise in
NADH/NAD ratio [3]. For several minutes after the arrest of oxidative
phosphorylation levels of ATP may be maintained by glycolysis. Glycolysis,
however, is unable to meet the demand of the beating heart for ATP for more
than a few minutes [5]. In addition, after 30 minutes, lactate accumulates in
the cell and cytospasmic pH decreases to 5.5-6 resulting in inhibition of
glycolysis [3, 6]. ADP levels increase rapidly, while ATP levels fall slowly to
about 50% of [ATP] at normoxic conditions after 30 minutes of ischemia [7].
Sodium-hydrogen exchanger (NHE), although relatively quiescent under
aerobic conditions, becomes activated by intracellular acidosis, causing the
extrusion of H+ and the influx of the concomitant Na+ [8]. Due to low ATP
levels the sarcolemmal Na+/K+ -ATPase and sarcoplasmic reticulum Ca 2+ ATPase become non-functional and cytoplasmic [Na+] and [Ca 2+] increase.
Na+ increase causes the Na+/Ca2+ exchanger to work in reverse, which
inbibits Ca 2+ efflux or even enhances the Ca 2+ influx [9, 10]. It has been
reported that with prolonged ischemia NHE is inhibited by extracellular
acidosis that eventually exceeds intracellular acidosis [11, 12]. Soon, the
5

mitochondrial electro-chemical gradient is almost entirely diminished resulting
in a great depression of the mitochondrial membrane potential. When in this
extreme state of stress mitochondria are likely to trigger necrosis (accidental
cell death associated with membrane rupture} and apoptosis (programmed
cell death}.
Although it is essential to return blood flow to the heart in order to
salvage the myocardium and preserve functionality of the organ, the process
of reperfusion itself causes additional deleterious effects not observed during
ischemia. This phenomenon is collectively referred to as ischemiareperfusion injury. When blood is reintroduced to an ischemic system, rapid
washout of extracellular H+ reactivates NHE, resulting in further intracellular
Na+ accumulation. Again, Ca2+ influx follows causing abnormally high
intracellular Ca2+ concentration. When oxygen is reintroduced to the
respiratory chain, ubiquinone can become partially reduced to
ubisemiquinone. This can in turn react with oxygen to produce superoxide
that is reduced to hydrogen peroxide by superoxide dismutase [5]. Hydrogen
peroxide, in the presence of ferrous ions, will form the highly reactive hydroxyl
radical through the Fenton reaction [5, 13]. These reactive oxygen species
(ROS}, which immediately increase slightly above normal when the heart
becomes ischemic and then dramatically upon reperfusion [14] are extremely
damaging to mitochondrial proteins. ROS have direct effects on complex 1
and complex 3 of the respiratory chain, as well as other iron sulphur proteins
6

[5]. In addition, ROS may cause oxidation of glutathione that may then form
mixed disulphides with proteins, which in turn inhibit protein pumps [15, 16].
Overall, it is thought that the combined effects of ROS and Ca2+ overload are
responsible for ischemia-reperfusion injury and determine whether the injury
is reversible. In particular, mitochondrial injury by these agents may lead to
the opening of mitochondrial permeability transition {MPT).

1.4 Mitochondrial Permeability Transition
The mitochondrial inner membrane barrier to diffusive ion fluxes is
essential in order to maintain the chemiosmotic gradient necessary to drive
ATP synthesis. During ischemia-reperfusion, several factors including matrix
calcium overload, high oxidative stress, high phosphate and low ATP
concentrations induce the opening of a non-selective pore in the inner
mitochondrial membrane, referred to as mitochondrial permeability transition
{MPT) or mitochondrial permeability transition pore. During reperfusion,
when oxygen is introduced ROS are produced and, with Ca 2+ overload that
happens during ischemia, MPT opens. This step takes place within 1-2
minutes and this delay enables postconditioning. Once open, MPT allows
unselective passage of any molecule up to 1.5kDa across the membrane.
This uncouples oxidative phosphorylation, by allowing unrestricted proton
movement across the membrane. The consequence of this is not only
prevention of ATP synthesis but rapid consumption (hydrolysis) of ATP by
7

reversing ATP synthase in a futile effort to re-establish the membrane
potential [17]. Under these conditions the ionic and metabolic homeostasis of
the mitochondria is disrupted and degradative enzymes such as
phospholipases, proteases, and nucleases are activated. Irreversible
damage will eventually occur and the cell will die via necrosis if MPT remains
open [3, 5]. A single opening of MPT is enough to depolarize the organelle
as described and will activate further MPT opening within the same
mitochondrion. This fully open state will result in a huge influx of small
molecules, after which osmotically responsible water will follow resulting in
matrix swelling. Swelling ultimately results in the rupture of the outer
membrane (inner membrane withstands swelling due to the unfolding of
cristae) and release of proapoptotic molecules in the intermembrane space
such as cytochrome c and apoptosis-inducing factor (AIF) [18, 19]. Both
cytochrome c and AIF instigate apoptotic processes and lead to cell death
[17-21].

1.5 lschemic Preconditioning
lschemic preconditioning (IPC) is an experimental physiological
phenomenon in which brief episodes of ischemia and reperfusion protect the
heart against subsequent lethal ischemic insult [22]. In the process of
preconditioning, a series of cell signaling events modify cellular components
in a manner that reduces myocardial damage from the sustained ischemia8

reperfusion event. The IPC mechanism results in reduced infarct size,
attenuating the incidence and severity of reperfusion-induced arrhythmias
and preventing endothelial cell dysfunction [23]. Several endogenously
released agents are involved in cardioprotection that results from
preconditioning and include: opioids, norepinephrine, free radicals,
adenosine, and bradykinin [24, 25].

1.6 Modes of Protection
In addition to ischemic preconditioning, several other modes of cardiac
preconditioning have been described. (1) Calcium preconditioning (CPC)
mimics IPC when calcium concentration increases briefly within the
cardiomyocyte. Exogenous increase in calcium administered just prior to
ischemia activates protein kinase C (PKC) and induces myocardial functional
protection similar to IPC [26]. (2) Potassium channel openers (KCOs) result
in cardiac preconditioning when administered prior to ischemia by increasing
K+ conductivity [27]. (3) Inhibition of sodium/proton exchanger by agents
such as cariporide ultimately prevents Ca 2+ overload and unusual Na+
gradients when administered prior to ischemia and thus causes decreased
cardiomyocyte damage [28, 29]. (4) lschemic post-conditioning describes a
phenomenon in which the heart undergoes ischemia and reperfusion with no
pretreatment of any kind. Shortly after reperfusion, however, the heart is
subjected to cycles of ischemia and reperfusion, resulting in similar extent of
9

protection as IPC [30).

1. 7 Cardioprotection by Potassium Channel Openers

Grover et al discovered that two drugs capable of cardioprotection,
cromakalim and pinacidil, were KCOs [27). Both were known vasodilators.
The vasodilator activity of these agents was attributed to their ability to
increase ATP-dependant K+ channel (KATP) conductance. In addition, there
was electrophysiological evidence that indicated that both activated KATP
channels in cardiac myocytes [31). Activation of K+ channels in smooth
muscle cells leads to hyperpolarization and consequent action potential
shortening [32]. Cardioprotective effects of cromakalim and pinacidil was
reversed by glyburide (glybenclamide) [27], which has been shown to be a
high affinity blocker of ATP-dependent K + channels [33). A variety of other
KCOs were shown to be cardioprotective when administered prior to
ischemia, including nicorandil, cromakalim, pinacidil, bimakalim, aprikalim,
and P-1075 [27, 34-36]. These findings were consistent throughout different
animal species [37-41 ]. Cardioprotective effects of all KCOs were reveresed
by the blocker glyburide.

1.8 M~toKArP Mediates Cardioprotection by KCOs

Initially, it was believed that the cardioprotection afforded by KCOs
was modulated via the sarcolemmal ATP-sensitive K+ channel (sarc~TP).
10

Potassium activation in the cell leads to hyperpolarization of the cell and
subsequent action potential shortening. Hyperpolarization due to increased
potassium conductance may bring the resting potential further from the
threshold that activates calcium channels; inhibiting calcium influx and
reducing ischemia. This view was significantly questioned when several
experiments showed that cardioprotection is possible without action potential
duration (APD) shortening [42-44]. Also, in 1991, Inoue et al identified an
ATP-sensitive potassium channel in the inner mitochondrial membrane in rat
liver through patch clamp experiments, and Paucek reconstituted and
partially purified ATP-sensitive potassium channel that was sensitive to
glibenclamide (K+ channel closer) from rat liver and beef heart mitochondria
[45, 46]. A few years later, in 1996, work by Garlid et al put forth the
hypothesis that it is the mitochondrial ATP-sensitive K+ channel (mitoKArP)
that is responsible for the cardioprotective effects of KCOs and not sarcKArP
[47]. This finding was based on several independent observations and
explained the paradoxical finding that the action potential shortening in
cardiac myocytes and cardioprotection through KCOs did not correlate. First,
it was demonstrated that various KCOs opened mitoKArP in isolated
mitochondria within their cardioprotective concentration range [47]. Second,
sarcKArP was shown to be almost completely insensitive to diazoxide, a
pharmacological agent with known cardioprotective properties, or 5-HD
(5-hydroxydecanoate ), which blocks cardioprotection, while mitoKArP,
11

assessed in isolated mitochondria, is sensitive to both in the pharmacological
dose range [4 7-49].
In 1997, Garlid et al [48] confirmed the mitoKArP hypothesis with the
following findings: although both diazoxide and cromakalim (non-selective
KCO) afforded similar levels of protection against ischemia-reperfusion injury,
cardioprotection via cromakalim was accompanied by some action potential
duration (APD) shortening, whereas no APD shortening was caused by
diazoxide, the selective mitoKArP opener, demonstrating that diazoxide does
not act via sarcKArP· Since this discovery, numerous laboratories have
provided evidence to support the paradigm that mitoKArP, and not the
sarcKArP, is the mediator of ischemic preconditioning and precondition by
KCOs [50-55].

1.9 MitoKATP During Normal Conditions
It is conceivable that mitoKArP evolved in order to provide a mode of
cardioprotection, via IPC. However, this protein appears to exist in all
mammalian species studied, including several that are not susceptible to
ischemic heart disease [56]. Thus, it has been proposed that mitoKArP plays
a role in cardiac physiology during normal conditions and protection against
ischemia happens to be a beneficial byproduct.
1.9.a MitoKATP in normal cell signaling
There is some evidence that mitoKArP plays a role in normal cell

12

signaling process that leads to cell growth. It has been shown that ouabain, a
ligand of Na/K-ATPase, stimulates mitochondrial ROS production via a Rasdependent pathway [57]. Among others, this ROS production is an element
that the ouabain and the cardioprotection pathways share in common,
thereby linking the two [58]. Furthermore, it has been shown that the ouabain
signaling pathway is blocked not only by ROS scavengers but also by 5-HD increasing support for the hypothesis that the two pathways are linked [58].
The interplays among these pathways in cardiomyocytes lead to changes in
the expression of several genes. [56].
1.9.b MitoK.A TP opening in high work state - maintenance of positive
ionotropy

During high work state, when the cardiomyocyte is undergoing high
rates of ATP production and consumption, electron transport is high and the
membrane potential significantly decreases. As Garlid explains in his review
[56], this observation is identical to any other battery system, where drawing
high currents ill decrease the output voltage. This decrease in membrane
potential will result in the contraction of the mitochondrial matrix (because
decrease in membrane potential decreases the influx of ions and the
osmotically obligated water that enters with them), and the expansion of the
inter-membrane space (IMS). However, mitoKATP, when open, provides a
parallel potassium conductance that counteracts this matrix contraction,
resulting in the preservation of matrix and IMS volume. IMS preservation is
critical in maintaining the association of VDAC (voltage-dependent ion
13

channel), which controls outer membrane permeability to ADP and ATP, and
creatine kinase. Creatine kinase phosphorylates creatine, using ATP
produced by the mitochondrial ATPase, creatine phosphocreatine and ADP.
The high-energy phosphate bond of phosphocreatine has more energy than
the bond of ATP, 10,300 calories per mole in comparison with 7,300.
Phosphocreatine presumably gets shuttled into the cytosol through VDAC
and holds enough energy to reconstitute the high-energy bond of ATP.
Therefore, this system provides an energy store in the cell and is incredibly
important in the heart, where high work states are very frequent [56]. It has
been proposed that endogenous signals open mitoKATP during high work state
in order to maintain matrix volume and the association between VDAC and
creatine kinase. Garlid and colleagues [56] tested the hypothesis that
mitoKATP opening is required for the positive inotropic response (increased
contractility) by testing mitoKATP inhibitors in this system. Consistent with the
hypothesis, these authors found that mitoKATP blockers (5-HD and TPP+)
prevented inotropic response indeed.

1. 10 MPT and mitoKATP
lschemic preconditioning as well as preconditioning by KCOs reduces
MPT opening and decreases infarct size [59-61]. In order to describe the
mechanism that acts in this situation, Karge et al [62] simulated ischemia in
isolated mitochondria and caused MPT opening by exposing them to high
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Ca 2+ and phosphate. Diazoxide (mitoKATP channel opener) and phorbol 12myristate 13-acetate (PMA, pharmacological agent that activates Protein
Kinase C (PKC) by mimicking diacylglycerol - a physiological PKC activator)
both blocked MPT opening and the release of cytochrome c, while 5-HD
(mitoKATP channel closer) reversed this effect [63]. These results supported
the hypothesis that the protective mechanism of blocking MPT operates
through PKC [49]. Working with genetically modified mice with cardiacspecific expression of recombinant PKCs, Baines et al [64] demonstrated that
PKCs activity inhibited MPT opening in heart mitochondria. Other studies
have demonstrated that inhibition of PKC by pharmacological agents blocks
protection via IPC [65]. Also, hearts from PKCs knock-out mice do not exhibit
protection by IPC [66]. In addition to PKCs involvement Kim et al [67]
suggested that MPT inhibition operated through a guanylyl cyclasedependent signaling pathway by showing that cyclic GMP (cGMP) prevented
MPT opening. Interestingly, it was shown that mitochondria swell in K+
medium after addition of Protein Kinase G ( PKG) and cGMP [68]. This
swelling is highly indicative of a potassium channel opening suggesting that
PKG + cGMP cause mitoKATP to open. In addition, KT5823, a specific
inhibitor of PKG blocked this effect, while mitoKATP specific opener, diazoxide,
reversed inhibition by KT5823 [68]. In 2006 our laboratory demonstrated the
mechanism by which mitoKATP opening inhibits MPT activation in heart, liver,
and brain mitochondria. In agreement with previous experiments, this
15

mechanism utilizes PKG and PKCE as obligatory intermediates [49]. Upon
activation in this process, mitoKATP increases ROS. Interestingly, ROS (in this
experiment H2 O2 ), in concentrations at least 50 times smaller than those that
induce MPT opening provides protection from MPT opening via PKCE
independent of mitoKATP, suggesting that small amounts of ROS may be
protective [49, 69]. These data suggest that mitoKATP opening protects the
heart from ischemia-reperfusion by inhibiting MPT and thus cell death by
apoptosis and necrosis (Figure 2).
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Figure 2. (Modified from [49])
The cardioprotective signaling pathway in mitochondria. Active PKG from the
cytosol, which cannot cross the outer membrane of the mitochondria,
phosporylates an unknown protein at the surface of the mitochondria. This
protein presumably activates PKCc1, that is thought to be bound to the outer
surface of the inner mitochondrial membrane. Then, PKCc1 phosphorylates
and thus opens mitoKATP, resulting in an influx of potassium ions. Matrix
potassium increase results in matrix alkalinization and eventually a small
increase in matrix H2O2 • This increase in H2O2 activates PKCc2, causing the
inhibition of MPT. PKCc1 and PKCc2 are identical enzymes localized in
different pools within the pathway. It is also known that this modest increase
in H2O2 activates a number of other kinases.
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1.11 Mechanism of Cardioprotection Induced by MitoKATP

The primary function of mitoKATP channels is to regulate mitochondrial
volume [70, 71 ]. It is absolutely essential to maintain appropriate
mitochondrial matrix volume, and thus vesicular integrity, in the face of the
ever changing environment of the inner membrane space, with numerous
ions, molecules, and water leaving and entering the inner membrane space.
This is largely accomplished by the regulation of K+ transport, via diffusion
and via mitoKATP [70, 71 ]. Diffusive uptake of K+ is exponential with voltage
and is thus highly sensitive to the mitochondrial membrane potential. K+
uptake is followed by uptake of phosphate (Pi) on the Pi/OH· exchanger,
followed by osmotically obligated water [72]. On the other hand, K+ leaves
the inner membrane space via the K+/H+ antiporter, again, followed by water.
In this way, the balance between the ion (and water) influx is balanced by the
activity of K+/H+ antiporter. During ischemia, the mitochondrial membrane
potential is low, mitochondria depolarize due to anoxia and mitochondrial
matrix contraction results. As a result, inner membrane space architecture
gets highly distorted, and ATP hydrolysis is accelerated due to disruption of
mitochondrial creatine kinase [71]. Increased K+ conductance through the
opening of mitoKATP may help to maintain inter-membrane space architecture
and slow down the hydrolysis of ATP, allowing the use of creatine as
substrate upon reperfusion [71].
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1.12 MitoKATP in Other Tissues
MitoKATP has been shown to provide protection in pancreatic beta-cells
by preventing the onset and development of diabetes in rats. The selective
mitoKATP opener, diazoxide, inhibited apoptosis by directly opening mitoKATP
and this effect was completely abolished by 5-HD [73]. As in the heart,
ischemia-reperfusion injury may also lead to apoptosis in the brain [74].
Mitochondria in the brain contain seven times more mitoKATP channels then
heart mitochondria [75]. There is support that mitoKATP protects the brain
against ischemia reperfusion injury in vivo models: diazoxide preserves
neuronal-vascular function after cerebral ischemia in piglets [76] and induces
protection induced by hypothermic circulatory arrest in canine models [77],
both effects were reversed by 5-HD. A study in cultured cerebellar granule
neurons, where H2O2 was used to simulate neuronal apoptosis, suggested
that mitoKATP provides neuroprotection by preserving mitochondrial inner
membrane potential [78].

1.13 The Argument
Diazoxide and 5-HD have become synonymous with mitoKATP opening
and closing, respectively. The paradigm that mitoKATP is the mediator of
preconditioning via KCOs has been questioned by a number of investigators
[79-83]. In particular, it has been proposed that diazoxide and 5-HD mediate
cardioprotection independently of mitoKATP [79, 81, 83]. This controversy has
19

be intensified by the lack of a molecular identity for mitoKATP· Throughout the
last six years or so, several investigators, most recently Minners [79] have
concluded that cardioprotection by diazoxide is afforded by respiratory chain
inhibition [81, 82, 84]. In fact, it has been known for almost forty years that
high doses of diazoxide significantly decrease mitochondrial respiration by
inhibiting succinate-dehydrogenase (SDH) [85]. These investigators fail to
take into account the differences in the concentrations of this drug in both
circumstances. Diazoxide inhibits SDH at high concentrations, while
cardioprotection is achieved in much lower doses. In fact, it is very
reasonable to suppose that most hydrophobic drugs, such as DZX, when
used in very high concentrations will embed themselves into the membrane
and cause physiological changes. It is also important to point out that these
arguments focus on diazoxide, ignoring the fact that many other mitoKATP
openers provide cardioprotection without inhibiting the respiratory chain.
The same three laboratories proposed that 5-HD, which is a hydroxy
derivative of decanoate, antagonizes the effect of diazoxide by being
metabolized like other medium-chain fatty acids in the heart. Again,
metabolism of 5-HD is already know from previous work [86]. 5-HD has a
very short (7 minute) biological half life in dogs [86] and blocks
cardioprotection when given 2 minutes, but not 8 minutes, before IPC [87].
These authors suggested that the short half life is due to 5-HD being
converted to 5-HD-CoA by mitochondria in the presence of ATP and CoA
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[56]. Those that have proposed this explanation for cardioprotection suggest
that 5-HD blocks cardioprotection by interfering with normal cardiac
metabolism, although do not explain how this may be. Again, these
arguments do not explain why glibenclamide [48] and HMR1098 [88] block
cardioprotection by diazoxide.
MitoKATP openers diazoxide, 3-NPA, 'I'ERACK, and PKG will be utilized
in our experiments. Therefore, they are briefly discussed in sections below.

1.14 3-NPA
3-Nitropropionate (3-NPA) is a widely distributed plant and fungal toxin
first identified by Morris et al in 1954 as the primary toxic agent of lndigofera
endecaphylla [89, 90].

It is produced on moldy crops such as sugarcane and

peanuts and causes severe neurological disorders in humans when
consumed in sufficient amounts [91-93]. 3-NPA is said to be a suicide
inhibitor of succinate
dehydrogenase (SDH),
Figure 3. 3-NPA (left), in its carbanion form, is
isoelectic with succinate (right).
c _ _ _ __ _ _ _ _ _ _ _ _ _ _ _ _ _ __ _ _ J

associated with the
tricarboxylic acid cycle and

complex II in the respiratory chain. Alston et al demonstrated that the dianion
form of 3-nitropropionate is the inhibitory form [90]. The carbanion form of
this compound is isoelectric with succinate (Figure 3), SDH substrate [90],
and reacts progressively with N-5 of the covalently bound flavin to form a
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covalent adduct [94] (Figure 4 ). This binding is irreversible [90, 94].
Chemical preconditioning with 3-NPA has been shown to have a protective
effect against ischemic hypoxic neuronal damage in vitro [95-97].
Interestingly, the symptoms of 3-NPA toxicity closely resemble those of
Huntington's disease and thus provide a research model for understanding
the mechanisms of Huntington's [98]. Several findings show that the type of
neuronal death induced by 3-NPA is dose-dependent [99]. In vivo and in rat
hippocampal cell cultures, intermediate doses of the compound result in
apoptosis [100], while high doses led to NMDA-receptor dependent
excitotoxic cell death. It is speculated that dependent on its concentration 3NPA can induce three different cellular responses: tolerance (preconditioning)
[96], apoptosis, or necrosis. 3-NPA addition caused a pronounced decrease
in [creatine phosphate/creatine] and a fall in [ATP/ADP] as well as
[GTP/GDP] [98]. It has been well established that reductions in energy
metabolism are neuroprotective. However, it is unlikely that preconditioning
via low doses of 3-NPA is an example of this phenomenon because 3-NPA
preconditioning is evident much later (several days) after normal ATP levels
and SDH activity have been reestablished [96]. It may therefore be
concluded that inhibition of SDH is not the mechanism by which 3-NPA is
protective in the brain.
Riepe et al hypothesized that ATP-sensitive potassium channels may
be responsible for the effect of administrating sub-lethal doses of 3-NPA after
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conducting electrophysiological studies on rat hippocampal slices [101 ].
Further investigation and in situ studies demonstrate that neuroprotection via
3-NPA was abolished by administration of glybenclamide and 5-HD [102].
Additionally, 3-NPA administration resulted in mitochondrial depolarization
and these effects were also blocked by 5-HD [102]. These results suggest
that mitoKATP plays a significant role in 3-NPA preconditioning in the brain.
Several studies also suggest that 3-NPA protects the heart from
ischemia-reperfusion injury. Experiments on a Langendorff apparatus
demonstrated that 3-NPA provides significant cardioprotection [103]. Ockaili
and coworkers demonstrated that 3-NPA induces an immediate and delayed
cardioprotective effect in the heart as indicated by a significantly decreased
infarct size compared with control animals. The mitoKATP selective opener, 5HD, abolished both the early and the delayed cardioprotective effects when
administered before ischemia-reperfusion [104]. This evidence indicates that
mitoKATP is a mediator in heart preconditioning and cardioprotection via 3NPA.
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1.15 Diazoxide
Diazoxide (3-methyl-7-chloro-1,2,4-benzo- thiadiazin-1, 1 dioxide)
(figure 5) is a synthetic drug that has been used as a diabetogenic agent, by
suppressing of insulin secretion in vivo and in
vitro [85]. It is the most potent beta-cell KArP
channel opener known and it successfully
hyperpolarizes the beta-cell, thereby inhibiting
Figure 5. Molecular
structure of diazoxide

insulin secretion [105] and by preventing

~ - - - - - - - - ~ apoptosis in pancreatic beta-cells of pre-diabetic
and diabetic rats [73]. Diazoxide is also used inter-venously to treat severe
hypertension as it relaxes arteriolar smooth muscle [106]. Both of these
clinical applications of diazoxide were widely used before the discovery of
ATP-sensitive potassium channels. In 1969, Schafer et al reported that
diazoxide inhibited succinate dehydrogenase (SDH), complex II of the
electron transport chain in isolated rat liver mitochondria and beef heart
submitochondrial particles [85]. Their findings demonstrated that in high
concentrations, diazoxide strongly inhibits succinate-supported respiration but
not NADH-linked substrate oxidation. Belyaeva et al and Szewczyk et al
reported that diazoxide (and other KCOs) also act on respiring mitochondria
[107, 108]. Their reports suggested that diazoxide effects on mitochondria
are pharmacologically irrelevant because its effect was very weak at
concentrations much higher than K1,2 values observed with sarcKArP [109]. In
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1996 Garlid et al reported that diazoxide was a very potent activator of the
ATP-sensitive potassium channel in intact mitochondria and proteoliposomes
containing recontituted mitoKATP [47]. No effect was observed on uninhibited
potassium flux, likely explaining the low potencies that Szewczyk and
Kelyaeva reported [4 7]. Due to the observation that diazoxide opens
mitoKATP channel at a concentration that has no effect on the sarcKATP
channel, focus shifted from sarcKATP to mitoKATP channel as mediator of
cardioprotection [4 7].

1. 16 'PeRACK

'I'sRACK is a selective PKCs (Protein Kinase C epsilon) activator
peptide. It is derived from PKCs and is eight amino acids long [HDAPIGYD].
PKC (Ca 2+-dependent protein kinase) is a serine/threonine kinase found
abundantly in many different cell types. PKCs is one PKC isozyme (one of
six) that is constitutively present in heart mitochondria [11 O]. There are many
reports that PKCs activation plays a critical role in transmitting a signal that
induces cardioprotection [68, 111-114]. Baines et al [64] and Karge et al [63]
have shown that PKC activation is able to inhibit MPT opening. Costa et al
[49] demonstrated that 'I'sRACK provides cardioprotection through mitoKATP
through the inhibition of MPT. This finding that 'I'sRACK provides
cardioprotection by mimicking ischemic preconditioning has been
demonstrated by a number of laboratories [111, 113, 115, 116].
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1.17 PKG
cGMP-dependent protein kinase (PKG) is an abundant
serine/threonine kinase activated by cyclic GMP (cGMP), in fact, it is the
major intracellular receptor of cGMP [117]. It is present in high amounts in
platelets, cerebellum, smooth muscle, cardiac muscle, hippocampus, dorsal
root ganglia, neuromuscular end plate, and the kidney vasculature. Low
levels have been detected in granulocytes, vascular endothelium,
chondrocytes, and osteoclasts. PKG phosphorylates a number of
physiologically relevant proteins involved in regulating the contractile activity
of smooth muscle cells, regulation of cell differentiation and proliferation,
inhibition of platelet aggregation and apoptosis [118, 119]. Han et al [120]
first suggested that PKG is involved in the signaling pathway that induces
cardioprotection via ischemic preconditioning in rabbit ventricular myocytes.
In their experiments, PKG was found to be responsible (at least in part) to
phosphorylation and activation of KATP channels. Selective PKG inhibitors
abrogated any effects [120]. Oldenburg et al [121] studied mitochondrial
ROS generation by bradykinin and concluded that PKG activation (in their
case by ROS) triggers preconditioning by opening mitoKATP· In order to
uncover the mechanism by which PKG acts on mitoKATP, Costa et al [68]
conducted light scattering experiments which demonstrated that active PKG
(and cGMP necessary to activate it) is indeed necessary to open mitoKATP in
vitro, and KT5823, a specific PKG inhibitor, blocked this effect. Interestingly,
the inhibition of PKG by KT5823 was reversed by the addition of the specific
27

mitoKATP opener diazoxide [68]. In addition, PKG-induced effect was
reversed by 5-HD (selective mitoKATP inhibitor) [68]. These investigations
suggest that active PKG activates mitoKATP by indirect phosphorylation, and
that this phenomenon is not limited to cardiomyocytes and has been
observed in brain and liver mitochondria [68].

1.18 Overall Hypothesis
Several investigators have suggested that cardioprotection afforded by
ischemic preconditioning is not mediated through mitoKATP but results from
the inhibition of Complex II of the electron transport chain, succinate
dehydrogenase. In this study, I have examined four chemically distinct and
unrelated pharmacological agents, all of which have been shown to open
mitoKATP, to demonstrate that the said cardioprotective effect mediated by
mitoKATP is entirely independent of SDH.
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2. Methods
2.1 Animals
Male rats of the Sprague-Dawley variety were used in all experiments.
The rats were about 2 months old and weighed 225-2499. They were
housed two per cage in a 24°C room and were fed and watered ad libitum.
Diet consisted of standard rodent formula chow from labDiet. All procedures
involving animals are in accordance with the American Physiological Society
"Guiding Principles in the Care and Use of Animals" and was approved by
Institutional Animal Care and Use Committee at Portland State University.

2.2 Mitochondrial Isolation
One or two rats were anesthetized with CO2 for 20-30 seconds and
immediately decapitated. An incision into the chest cavity was made using
surgical scissors and hearts were quickly removed and rinsed in ice-cold
Buffer A (250mM sucrose, 10mM HEPES pH 7.2, 5mM K-EGTA, and
1mg/ml fatty-acid free BSA). Hearts were squeezed manually until most of
the blood was removed. The hearts were then finely minced in Buffer A
containing 1mg/ml protease (Nagarse) for approximately 40 seconds. The
suspension was then diluted with Buffer A and homogenized with a motorized
Teflon pestle until the homogenate looked uniform (about 45 seconds). The
entire homogenate was then divided equally into two 30ml plastic tubes and
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diluted with additional Buffer A to bring the volume just shy of the top of the
tubes. These were then spun at 1700g for 3 minutes. The resulting
supernatant containing the mitochondria was decanted into clean, ice-cold
tubes and further centrifuged at 9000g for 5 minutes. Pellet from the first spin
containing blood cells and cellular fractions was discarded. The pellet from
the second spin was carefully resuspended in Buffer B (Buffer A minus BSA)
and centrifuged again for 4 minutes at 23009. The resulting supernatant was
centrifuged one more time to pellet the isolated mitochondria at 9000g for 5
minutes. This final mitochondrial pellet was resuspended in about 200µL of
Buffer B and stored on ice.

2.3 Protein Measurement
All protein was measured in Thermo Spectronic Genesys 20 using the
Biuret Method first described by Gornall [122].

2.4 Measurement of Mitochondrial Volume
Mitochondrial matrix volume was measured by light scattering
technique as first described by Beavis [123]. Mitochondria respond to
osmotic pressure of their environment by taking up, or pumping out of water.
When osmolarity outside the mitochondria increases and salt begins to enter
the mitochondrial membrane - obligated water follows resulting in
mitochondrial matrix swelling; shrinking occurs due the reverse. When
mitoKATP is opened, regardless of the cause, potassium ions and water flow
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into the matrix and swelling is observed. Matrix contraction is observed when
mitoKArP is closed. Therefore, mitochondrial swelling and shrinking in a
potassium rich medium is indicative of the state of mitoKArP· The light
scattering technique utilizes a Brinkmann PC 700 colorimeter light probe
fitted with a 520 nm filter. A small mirror about 1 cm below the light source
reflects the light that has not been absorbed back into the system. Increase
in matrix volume is accompanied by a decrease in the intensity of light
scattered by the suspension, because as mitochondria swell, they absorb
more (and therefore scatter less) light [123, 124]. The probe is normally
immersed in 2 ml of assay medium and mitochondria protein (0.1 mg/ml)
suspension, which is constantly stirred and maintained at 30°C. Absorbance
is measured and quantified [123] using a computer program developed in our
laboratory. It is based on the principle that reciprocal absorbance (A) of the
mitochondrial suspension (proportional to matrix volume, which depends on:
medium osmolality, matrix solute content, and the concentration of
mitochondria [123], when corrected for the extrapolated absorbance at infinite
protein concentration is linearly related to the matrix volume. This
absorbance is then converted to beta(•), which corrects for variations in
protein concentraion:

where• is the machine constant (0.25 in the case of our apparatus), A is
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absorbance, Pis mitochondrial concentration (mg/ml), and Ps (equals
1mg/ml) is introduced to make • a scaled dimensionless quantity (123].
Conversion to • allows comparison of multiple experiments. The light
scattering assay medium contains 120mM KCI, 10mM HEPES (pH 7.2),
0.1mM EGTA, 10mM succinate, and 5mM phosphate. Rotenone (5µM),
which inhibits complex I of the electron transport chain and the reverse
electron transfer from complex II to complex I as well as oligomycin (0.67µM),
which inhibits ATP synthesis by the ATPase and consequent decrease in
membrane potential are also added to all assay media.
MitoKATP openers and closers were added to the assay media in
appropriate concentrations to determine their effect on mitoKATP (swelling
indicates open channel, shrinkage - closed).

2.5 Measurement of Mitochondrial Respiration
Respiration was measured using a Yellow Springs Instruments oxygen
electrode (Clark polarographic sensor), model 53. Electrode is connected to
a chamber containing 2ml of respiration solution of constant temperature
(25°C). At normal conditions this chamber contains a set amount of oxygen
(960ng atoms O in 2ml at 25°C). After the addition of respiring mitochondria,
the oxygen amount decreases and this linear rate is plotted on the computer
that is connected to the electrode. Chemicals were added to the assay
chamber containing the assay medium and mitochondria and their effect on
respiration were observed. Respiration assay medium contains: 11 0mM
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sucrose, 10mM HEPES pH 7.2, 2.5mM Pi, 0.1mM EGTA, 0.5mM MgCl2, and
10mM succinate. 5µM rotenone was also added to each run in order to
inhibit Complex I of the electron transport chain.

2.6 Solutions
All solutions were made with deionized water from Millipore Synergy
185. For contents of each medium please refer to sections above.

2. 7 Chemicals and Reagents
Most chemicals were purchased from Sigma Chemical Co. except for
PKG (Promega), cGMP (EZ Biolabs), and 'l'cRACK (EZ Biolabs).

2.8 Data Analysis
All data analysis was done using the program ORIGIN by Microcal.
Respiration data were analyzed as follows. Each dose was assessed in an
independent run. Mitochondria and rotenone were added immediately (at
time 0), 100 seconds later CCCP (carbonyl cyanide m-chloro phenyl
hydrazone, a mitochondrial uncoupling agent) (35µM) was added, 100
seconds after that the appropriate drug was added. The CCCP alone and
CCCP+drug rates were converted into (ng atoms oxygen)*(min-1 )*(mg protein-

1). Then a ratio of (CCCP + drug) rate/(CCCP) rate was calculated and
multiplied by 100% in order to calculate"% of control". Thus, each individual
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run had its own no drug control to account for slight differences in pipetting,
stirring, mitochondrial viability, and so on in different runs.
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3. Results
3.1 Diazoxide
Diazoxide opens mitoKATP at 30µM in rat heart mitochondria. Figure
6 demonstrates the swelling that is associated with mitoKATP opening due to
the presence of diazoxide. This opening is reversed by 5-HD. Diazoxide
concentrations above 1mM inhibit succinate-supported respiration by 75% in
rat heart mitochondria, IC50 = 140µM (Figure 7).

3.2 3-NPA
3-NPA opens mitoKATP at 1OnM in rat heart mitochondria (Figure 8).
This opening was reversed by 5-HD. 3-NPA inhibits succinate supported
respiration, IC50 1.05mM.

3.3 PKG
PKG + cGMP do not inhibit succinate-supported respiration below 96%
of full function in the dose range tested. Figure 1Ob demonstrates the raw
respiration data for these experiments, while figure 1Oa shows the doseresponse.
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3.4 'PeRACK
'PsRACK does not inhibit succinate-supported respiration below 92%
of full function in the presence of rotenone within the tested dose (Figures
11 a-b).
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Figure 6. Light scattering assay results demonstrating that diazoxide (30µM)
opens mitoKATP in KCI medium. 5-HD reverses this opening in the presence
of ATP (n = 4).
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Figure 7. Respiration assay results demonstrating that diazoxide inhibits
succinate-supported respiration. Hill slope = -2.4, IC 50=11 OµM, sucrose
medium, in the presence of rotenone (n = 3).

38

3-NPA Opens MitoKArP
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Figure 8. Light scattering assay demonstrating that 3-NPA (1 OnM) opens
mitoKATP in isotonic KCI medium, in the presence of succinate, rotenone, and
oligomycin. This effect is reversed by 5-HD (n = 1).
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Figure 9. Respiration assay demonstrating that 3-NPA inhibits succinatesupported respiration in sucrose medium, in the presence of rotenone. Hill
Slope= -1.1, IC 50 = 1.05mM (n = 4).
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PKG does not Inhibit Respiration
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Figure 10a. Respiration assay demonstrating that PKG+ cGMP do not
inhibit succinate-supported respiration in sucrose medium, in the presence of
rotenone (n=3).
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PKG + cGMP do not Inhibit Respiration
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Figure 1Ob. Raw traces from respiration assay demonstrating that PKG +
cGMP do not inhibit succinate-supported respiration in sucrose medium, in
the presence of rotenone (n=3). (1 unit = amount of kinase required to
incorporate 1pmol of phosphate into the test heptapeptide (RKRSRAE) per
minute, at 30•C)
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Figure 11 a. Respiration assay showing that 'l'eRACK does not inhibit
succinate-supported respiration in the tested range. Sucrose medium, in the
presence of rotenone (n=3).
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'PeRACK does not Inhibit Respiration
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Figure 11 b. Raw traces from respiration assay demonstrating that 'l'sRACK
does not inhibit succinate -respiration in the tested range. Sucrose medium,
in the presence of rotenone (n=3).
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4. Discussion
In 1986, Murry et al. described a paradoxical phenomenon whereby
brief ischemic insults reduce damage to the heart caused by a subsequent,
prolonged ischemic event [22]. Since 1989, when Grover et al. suggested
that opening KATP channels protects the heart from ischemia-reperfusion
injury, there has been a growing interest in investigating the details of this
mechanism. Although the classical sarcolemal KATP channel was though to
be the mediator of this cardioprotective pathway [125-127], compounding
evidence suggested that the mitochondrial KATP channel, located in the inner
mitochondrial membrane, was responsible for this effect [45, 4 7, 54, 55].
Garlid et al demonstrated that it is the mitoKATP channel that is the site of
action of all KATP channel openers [48]. This shift of paradigm has stirred a lot
of debate as the details of this cardioprotective mechanism are investigated.
Some of the difficultly in pinpointing the mechanism by which mitoKATP
induces cardioprotection lies in the fact that molecular identity of this channel
remains unclear. Indeed, what is known about mitoKATP comes largely from
pharmacological investigation. SarcKATP channels have been molecularly
defined as an octamer composed of four pore-forming inwardly-rectifying
potassium (Kir6.1 and Kir6.2) subunits and four sulfonylurea receptors
(SUR2A), which confer a regulatory role and a sensitivty of the channel to
ATP and pharmacological regulators [128]. MitoKATP channels share some
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pharmacological, and thus likely structural, properties with the classical
sarcKATP counterpart. Both channels are activated by pinacidil and inhibited
by glibenclamide [46, 48]. In order to study the mechanism of
cardioprotection, which has been suggested to operate through mitoKATP, it is
crucial to utilize specific activators and inhibitors of this channel. Obviously, it
is also important to ensure that the specific pharmacological agents don't
have effects on other, relevant systems.
Diazoxide and 5-hydroxydecanoate have been utilized as a selective
mitoKATP channel opener and closer, respectively. Several investigators,
most recently Minners et al [79], have rejected the role of mitoKATP in
cardioprotection on the basis that diazoxide (and 5-HD) effects that have
been attributed to mitoKATP are actually due to these drugs' effects on
mitochondrial respiration. Therefore, it was a goal of this study to investigate
whether the observed effect can be attributed to respiratory inhibition instead
of mitoKArP activity.
It was reported almost forty years ago that at high doses diazoxide
inhibits succinate dehydrogenase, complex II of the electron transport chain
[85]. Indeed, all hydrophobic drugs including diazoxide (and pinacidil,
another KArP channel opener) exhibit concentration-dependent inhibition of
the respiratory chain. This is due to their tendency to embed in the
hydrophobic membrane and cause a plethora of effects. This is further
supported by the observation that diazoxide is not entirely specific to SDH
[129]. The results of the current study strongly suggest that diazoxide inhibits
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succinate-supported respiration at high doses (IC50 = 11 0µM) down to 30%
respiratory activity at about 1mM diazoxide (figure 7), as previously
described. However, these concentrations are in excess of those necessary
to open mitoKATP (figure 6). In fact, the K1, 2 for diazoxide mitoKATP opening is
merely 3µM (Garlid 1996). In our studies, 30µM diazoxide is used in light
scattering assays in order to ensure complete channel opening. Even at this
concentration, no significant respiratory inhibition is observed.
At high concentrations 3-NPA acts as a suicide inhibitor of SDH by
binding irreversibly to the enzyme and preventing it from further participating
in its metabolic roles. Figure 9 demonstrates that the current study supports
these claims; the IC50 = 1.05mM. However, at much lower concentrations
(10nM, figure 8) 3-NPA seems to be capable of opening mitoKATP· At this low
concentration, 3-NPA appears to have no effect on respiration. It is important
to mention here that replicates are necessary to determine the exact dose
range at which 3-NPA opens mitoKATP in our light scattering system.
The influx of K+ ions through mitoKATP, observed as swelling during
light scattering experiments, is a respiration driven process. The
chemiosmotic gradient that is maintained by mitochondria during normal
respiratory conditions is the same gradient that drives K+ into the matrix. If
the concentrations of diazoxide and 3-NPA that are used to open mitoKATP
inhibit respiration, then this swelling would not be observed (significantly
decreased amount of swelling or even shrinkage would be observed),
because inhibition of respiration decreases or abolishes this gradient.
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Some investigators [79] imply that the observed cardioprotection
results from inhibition of SDH, since diazoxide, a known SDH inhibitor, has
been used as a model mitoKATP opener. However, my results demonstrate
(figures 10a-b, 11 a-b) that other mitoKATP openers, such as PKG and
'PERACK, do not have a significant effect on SDH function. They open
mitoKATP at 0.25units/µL and 0.5µM, respectively [68]. PKG and 'l'ERACK do
not activate mitoKATP directly, however, but act upstream of mitoKATP in the
cardioprotection pathway. This fact complicates the current issue and
experiments with compounds that activate niitoKATP directly, but have no
effect on any part of the respiratory chain, are necessary; such drugs were
unavailable for the current study. Interestingly, glibenclamide, a drug used to
inhibit KATP channel opening, is known to inhibit SDH as well as mitoKATP
opening, again demonstrating that that the mitoKATP effect is not explained by
SDH inhibition.
It has been suggested that ROS (reactive oxygen species) that are
produced during respiratory inhibition are responsible for cardioprotection,
giving a mechanism for cardioprotection via SDH inhibition. Indeed, ROS is
central in all cardioprotection models, including the mitoKATP hypothesis. A
small amount of ROS, regardless of its origin, protects the heart from
ischemia [49, 130-133]. This can be clearly demonstrated by including ROS
scavengers in an assay that measures cardioprotection or mitoKATP activity
[131 ]. ROS scavengers also block preconditioning in Langendorff assays. In
every case, the resulting effect is identical to that of 5-HD - abolition of
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cardioprotection. Small amounts of ROS are known

tq activate PKCE by

oxidizing the zinc fingers the enzyme and changing its conformation [134].
PKCE is a critical element in all modes of cardioprotection as it is thought to
phosphorylate and open mitoKATP [49]. Cardioprotective amounts of ROS,
therefore, activate mitoKATP through PKCs. It has also been shown that
inhibition of the respiratory chain produces ROS [79]. It is therefore
conceivable that the observed cardioprotective effect includes both slight
respiratory inhibition and activation of mitoKATP· If mild inhibition causes
some respiration inhibition and therefore causes a production of a small
amount of ROS then this ROS could in turn activate and open mitoKATP
resulting in cardioprotection. In short, it is possible that diazoxide and 3-NPA,
in small doses, inhibit respiration by an amount that does not cause
apoptosis, but causes the production of a small amount of ROS which in turn
activates PKCE, which finally activates mitoKATP and provides
cardioprotection, and do not activate mitoKATP directly.
However, it is highly unlikely that the small amount of respiratory
inhibition we observed in the mitoKATP opening doses has any effect on ROS
production. In order to test above hypothesis, it would be necessary to
measure ROS production after addition of 3-NPA and to test if, perhaps,
marginal inhibition of SDH by an SDH-specific inhibitor (such as malonate)
causes cardioprotection in situ. At this time there is no known mechanism by
which SDH is capable of producing ROS, which is generally produced by
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Complex I and Complex Ill. In addition, recently, Drose et al [83]
demonstrated that diazoxide does not generate ROS from the respiratory
chain, making the above hypothesis even less likely. Controversy on this
topic remains however, since Busija et al demonstrated that both 3-NPA and
diazoxide increase mitochondrial ROS in the brain [135].
Ardehali et al have demonstrated that SDH is a part of a protein
complex that is capable of transporting potassium ions, implying that SDH is
in fact mitoKATP, or that the two proteins are closely associatedb [136]. This
group suggests that the ability of SDH to regulate mitoKATP activity is entirely
independent from its function in the electron transport channel [136]. A very
recent study by Wojtovich and Brookes provides additional evidence that
SDH and mitoKATP are closely associated [137]. They demonstrated that
malonate, a competative inhibitor of SDH, opens mitoKATP channel even
when the mitochondria are respiring on complex I substrates (glutamate and
malate), at concentrations much lower than those necessary to inhibit SDH
(137]. These data are in agreement with the dose-dependant effects of SDH
inhibitors present in the current study. Interestingly, it has also been
demonstrated that I PC decreases SDH activity [138]. From these data it can
be speculated that during IPC or preconditioning by pharmacological agents,
SDH decreases its function as a Citric Acid Cycle enzyme and electron
transport chain enzyme and becomes involved in channeling potassium ions.
This would also give an evolutionary reason for why SDH is imbedded in the
inner membrane of the mitochondria. It is well established that the
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mitochondrial shape is highly dynamic thus quick volume regulation
mechanism seems necessary. Although this hypothesis would explain why
SDH, which does not pump protons in the electron transport chain, is
embedded in the membrane, it does not explain why some mitoKATP channel
openers seem to have no effect on SDH and why some mitoKATP channel
closers also inhibit SDH activity. In order to test this hypothesis, it would be
necessary to confirm the speculation that SDH is capable of shuttling K+ and
measure SDH enzymatic activity at the same time as K+ transport (or
mitoKATP activity).
It is well known that many of the agents used in studying cardiac
preconditioning have other effects on the heart, seemingly unrelated to their
effects on the mitoKATP channel. It would be ideal to study the effects of these
agents in situ, without disruption of cardiac myocytes. It is likely that
mitochondrial isolation greatly disrupts the natural shape of each
mitochondrion. At this point, unfortunately, there are no available techniques
to do this.
The dose-response curves for both 3-NPA and diazoxide yielded a Hill
slope that is greater than 1 (figures 7, 9). It is important to point out that the
system we tested is not an isolated one. Mitochondria purified in a crude,
differential centrifugation manner was utilized in all our assays. Therefore, it
is not feasible to create a perfect dose response curve with a Hill slope of 1.
For such an experiment, in order to describe the exact binding manner of
drug to SDH, it would be necessary to work with isolated SDH. In both cases
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the Hill slope indicates some degree of cooperative binding. In fact, it is
impossible to determine, in the present study, whether these drugs are acting
only on SDH, and not having other unknown effects on the electron transport
chain. Conceivably, it is possible that both diazoxide and 3-NPA affect other
components of the electron transport chain causing an increase in ROS from
complexes I or Ill. The current design of the study is, however, more relevant
to the physiological conditions that we were attempting to assess.
Additionally, the purpose of this study was not to obtain exact drug
concentrations, but to assess whether or not succinate-supported respiration
is significantly inhibited in doses that are used for mitoKATP opening.
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5. Conclusions
Cardiac disease is the most common cause of death in the United
States and in the world, therefore, understanding the details of its mechanism
is of great importance to public health. lschemic preconditioning, in
particular, is an interesting phenomenon with a possibility of wide implications
in the clinical field. Understanding how it works and how it can be
manipulated is crucial.
The goal of the research presented in this thesis was to clarify if
preconditioning by potassium channel openers is through the inhibition of
succinate dehydrogenase, complex II of the electron chain, as has been
claimed by some investigators, or if this kind of preconditioning is mediated
by mitochondrial ATP-sensitive potassium channel. The results of this study
indicate that the doses of potassium channel openers used to open mitoKArP
in light scattering assays are insufficient to cause any significant respiratory
inhibition. In addition, PKG and 'I'ERACK, which are known to open mitoKArP
do not inhibit respiration at any dose tested.
Therefore, it appears that preconditioning by diazoxide, 3-NPA, PKG,
and 'I'ERACK is mediated by mitoKArP as previously suggested and not
through the inhibition of succinate dehydrogenase. Many possible directions
of further studies exist to clarify the exact mechanism of cardiac
preconditioning.
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